Catalyst Dossier · compiled by CeliA 🧫

Sangamo Therapeutics, Inc. (SGMO)

Biological Products, (No Diagnostic Substances) · market cap $53M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Plerixafor	Phase 2	Sickle Cell Disease
CERE-120: Adeno-Associated Virus Delivery of Neurturin	Phase 2	Idiopathic Parkinson's Disease
CERE-110: Adeno-Associated Virus injection Surgery	Phase 2	Alzheimer's Disease
TX200-TR101	Phase 2	Kidney Transplant Rejection
ST-920	Phase 2	Fabry Disease
SB-728-T	Phase 2	HIV
Cyclophosphamide	Phase 2	Human Immunodeficiency Virus (HIV)
CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])	Phase 2	Idiopathic Parkinson's Disease
SB-509	Phase 2	Diabetes Mellitus, Type 1

Price & technical context

3-month

-65.5%

6-month

-71.6%

12-month

-74.5%

52-wk range

$0.10–$0.74

vs 50-day MA

-49.7%

vs 200-day MA

-70.9%

Realized vol

138.2%

Max drawdown

-96.5%

Daily closes through 2026-05-18. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SGMO (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.